Genetics of Alzheimer’s Disease

Neurotherapeutics

Volumn 11, Issue 4, 2014, Pages 732-737

  Guerreiro, Rita ^a   Hardy, John ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Genetics; Genome wide association studies; Next generation sequencing

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN TREM2; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; TREM2 PROTEIN, HUMAN;

ALZHEIMER DISEASE; DEMENTIA; FAMILY STUDY; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENOMICS; HEREDITY; HUMAN; REVIEW; ALLELE; FAMILY; GENETICS; GENOME-WIDE ASSOCIATION STUDY; PEDIGREE; RECESSIVE GENE;

ALLELES; ALZHEIMER DISEASE; FAMILY; GENES, RECESSIVE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MEMBRANE GLYCOPROTEINS; PEDIGREE; RECEPTORS, IMMUNOLOGIC;

EID: 84919863377     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-014-0295-9     Document Type: Review

References (42)

1. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349(6311):704-706. doi:10.1038/349704a0.
2. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43(8):1467-1472.
3. Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995;376(6543):775-778. doi:10.1038/376775a0.
4. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375(6534):754-760. doi:10.1038/375754a0.
5. Pulst SM. Genetic linkage analysis. Arch Neurol 1999;56(6):667-772.
6. Bras J, Guerreiro R, Hardy J. Use of next-generation sequencing and other whole-genome strategies to dissect neurological disease. Nat Rev Neurosci 2012;13(7):453-464. doi:10.1038/nrn3271.
7. Guerreiro R, Bras J, Hardy J. SnapShot: genetics of Alzheimer's disease. Cell 2013;155(4):968- e1. doi:10.1016/j.cell.2013.10.037.
8. Hardy J, Singleton A. Genomewide association studies and human disease. New Engl J Med 2009;360(17):1759-68. doi:10.1056/NEJMra0808700.
9. Jones L, Holmans PA, Hamshere ML, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One 2010;5(11):e13950. doi:10.1371/journal.pone.0013950.
10. McGeer PL, McGeer EG. The possible role of complement activation in Alzheimer disease. Trends Mol Med 2002;8(11):519-523.
11. Velazquez P, Cribbs DH, Poulos TL, Tenner AJ. Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Nat Med 1997;3(1):77-79.
12. Andersen OM, Reiche J, Schmidt V, et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A. 2005;102(38):13461-13466. doi:10.1073/pnas.0503689102.
13. Willnow TE, Andersen OM. Sorting receptor SORLA--a trafficking path to avoid Alzheimer disease. J Cell Sci 2013;126(Pt 13):2751-2760. doi:10.1242/jcs.125393.
14. Alperovitch A, Boland A, Delepoine M, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013;45(12):1452-1458. doi:10.1038/ng.2802.
15. Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007;39(2):168-177. doi:10.1038/ng1943.
16. Pottier C, Hannequin D, Coutant S, et al. High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry 2012;17(9):875-879. doi:10.1038/mp.2012.15.
17. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009;461(7265):747-753. doi:10.1038/nature08494.
18. Pritchard JK. Are rare variants responsible for susceptibility to complex diseases? Am J Hum Genet 2001;69(1):124-137. doi:S0002-9297(07)61452-61459 [pii]10.1086/321272.
19. Sebat J, Levy DL, McCarthy SE. Rare structural variants in schizophrenia: one disorder, multiple mutations; one mutation, multiple disorders. Trends Genet 2009;25(12):528-535. doi:10.1016/j.tig.2009.10.004.
20. Hou L, Faraci G, Chen DT, et al. Amish revisited: next-generation sequencing studies of psychiatric disorders among the Plain people. Trends Genet 2013;29(7):412-418. doi:10.1016/j.tig.2013.01.007.
21. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. New Engl J Med 2009;361(17):1651-1661. doi:10.1056/NEJMoa0901281.
22. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. New Engl J Med 2013;368(2):117-127. doi:10.1056/NEJMoa1211851.
23. Guerreiro RJ, Lohmann E, Bras JM, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013;70(1):78-84. doi:10.1001/jamaneurol.2013.579.
24. Paloneva J, Manninen T, Christman G, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet 2002;71(3):656-662. doi:10.1086/342259.
25. Guerreiro RJ, Lohmann E, Kinsella E, et al. Exome sequencing reveals an unexpected genetic cause of disease: NOTCH3 mutation in a Turkish family with Alzheimer's disease. Neurobiol Aging 2011. doi:S0197-4580(11)00405-2 [pii]10.1016/j.neurobiolaging.2011.10.009.
26. Bras J, Verloes A, Schneider SA, et al. Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. Hum Mol Genet 2012;21(12):2646-2650. doi:10.1093/hmg/dds089.
27. Guerreiro R, Bras J, Hardy J, Singleton A. Next Generation Sequencing Techniques in Neurological Diseases: Redefining Clinical and Molecular Associations. Hum Mol Genet (in press).
28. Nalls MA, Guerreiro RJ, Simon-Sanchez J, et al. Extended tracts of homozygosity identify novel candidate genes associated with late-onset Alzheimer's disease. Neurogenetics 2009;10(3):183-190. doi:10.1007/s10048-009-0182-4.
29. Ghani M, Sato C, Lee JH, et al. Evidence of recessive Alzheimer disease loci in a Caribbean Hispanic data set: genome-wide survey of runs of homozygosity. JAMA Neurol 2013;70(10):1261-1267. doi:10.1001/jamaneurol.2013.3545.
30. Di Fede G, Catania M, Morbin M, et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009;323(5920):1473-1477. doi:10.1126/science.1168979.
31. Wingo TS, Lah JJ, Levey AI, Cutler DJ. Autosomal recessive causes likely in early-onset Alzheimer disease. Arch Neurol 2012;69(1):59-64. doi:10.1001/archneurol.2011.221.
32. Clarimon J, Djaldetti R, Lleo A, et al. Whole genome analysis in a consanguineous family with early onset Alzheimer's disease. Neurobiol Aging 2009;30(12):1986-1991. doi:10.1016/j.neurobiolaging.2008.02.008.
33. Baron M, Gomez-Tortosa E, Bochdanovits Z, et al. Extended kindred with recessive late-onset Alzheimer disease maps to locus 8p22-p21.2: a genome-wide linkage analysis. Alzheimer Dis Assoc Disord 2012;26(1):91-95. doi:10.1097/WAD.0b013e318215aaf4.
34. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. New Engl J Med. 2013;368(2):107-116. doi:10.1056/NEJMoa1211103.
35. Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H. TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. PLoS Med 2007;4(4):e124. doi:10.1371/journal.pmed.0040124.
36. Frank S, Burbach GJ, Bonin M, et al. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 2008;56(13):1438-1447. doi:10.1002/glia.20710.
37. Piccio L, Buonsanti C, Mariani M, et al. Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol 2007;37(5):1290-1301. doi:10.1002/eji.200636837.
38. Krabbe G, Halle A, Matyash V, et al. Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One 2013;8(4):e60921. doi:10.1371/journal.pone.0060921.
39. Griciuc A, Serrano-Pozo A, Parrado AR, et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013;78(4):631-643. doi:10.1016/j.neuron.2013.04.014.
40. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12(10):383-388.
41. Karran E, Hardy J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurolgy 2014. doi:10.1002/ana.24188.
42. Karran E, Hardy J. Antiamyloid therapy for Alzheimer's disease--are we on the right road? New Engl J Med 2014;370(4):377-378. doi:10.1056/NEJMe1313943.